GLP-1 therapies are reshaping the pharmaceutical landscape. Originally developed for Type 2 diabetes, these treatments are now in high demand for chronic weight management—sparking a global manufacturing surge. Meeting the moment means more than increasing capacity. It requires smart planning, innovative design, and a long-term vision. Read the full article: https://lnkd.in/gtAxni3Q
GLP-1 therapies are a prime example of how innovation can redefine markets. Initially developed for Type 2 diabetes, drugs like Ozempic, Wegovy (Novo Nordisk), and Mounjaro, Zepbound (Eli Lilly and Company) are now in high demand for chronic weight management—driving a global surge in manufacturing. Scaling up isn’t just about more capacity. Leading manufacturers like Novo Nordisk, Eli Lilly, and others are investing in smarter, more resilient production models. Meeting this moment requires strategic foresight, innovative facility design, and a long-term vision to keep pace with both demand and innovation.
Creating Mumbai Biocluster| Biosimilar Evangelist
1wBig names. Big questions. Big decisions ahead. Join us as we set the stage for one of the most consequential dialogues in Indian biopharma this year! Our Plenary Panel Reveal is here – bringing together leaders shaping the future of GLP-1 therapies in India. Don’t miss this landmark conversation that could redefine diabetes, obesity, and cardiovascular care in India. 🗓️ Save the Date: 25–26 September 2025 📍 Venue: The Lalit, Mumbai Be a part of the dialogue that matters. Be a part of #PCG2025. Register today: https://www.linkedin.com/feed/update/urn:li:activity:7357603601667518465